Meiragtx Is A Clinical Stage Genetic Medicines Company Dedicated To Developing Innovative Therapies For Both Rare And Prevalent Diseasesthe Company Is Listed On The Nasdaq Under The Ticker Symbol Mgtxmeiragtx Utilizes Advanced Technologies And Comprehensive Manufacturing Capabilities To Harness The Potential Of Genetic Therapies The Company Specializes In Viral Vector Technologycreating Safe And Effective Viral Vectors For Gene Therapy Applicationsit Has Also Developed A Riboswitch Gene Regulation Platform That Allows For Precise Control Of Gene Expressionwhich Has Applications In Treating Various Disordersincluding Metabolic Diseases And Cancermeiragtx Operates Five Manufacturing Facilities Globallywith Two Licensed For Good Manufacturing Practicegmpviral Vector Productionsupporting Its Clinical Pipeline From Early Development To Commercial Supply Meiragtx Is Advancing A Broad Pipeline Of Late Stage Clinical Programsincluding Gene Therapies For Parkinsonae S Diseasetreatments For Radiation Induced Xerostomiaand Therapies For Aipl1 Associated Retinal Dystrophythe Company Is Also Exploring Metabolic Peptides And Applying Its Technology To Cell Therapies For Oncology And Autoimmune Diseases
No conferences found for this company.
| Company Name | Meiragtx Uk Ltd |
| Country |
United Kingdom
|
| Address | N/A |
| Telephone | N/A |
| N/A |
